Top Markets
Coin of the day
MGC Pharmaceuticals Limited MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited

MXC
株式のランク #39834
MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established... MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.
株価
$0.27239819
最終同期: 2024-04-29
時価総額
$330.42K
変化(1日)
0.52%
変化(1年)
0.00%
AU
取引 MGC Pharmaceuticals Limited (MXC)

カテゴリー

MGC Pharmaceuticals Limited(MXC)の配当利回りの履歴
MGC Pharmaceuticals Limited(銘柄コード: MXC)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
MGC Pharmaceuticals Limited(MXC)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)